These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10653205)

  • 1. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
    Versiani M; Amin M; Chouinard G
    J Clin Psychopharmacol; 2000 Feb; 20(1):28-34. PubMed ID: 10653205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant efficacy of reboxetine in patients with severe depression.
    Montgomery S; Ferguson JM; Schwartz GE
    J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM; Mendels J; Schwart GE
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H; Van Moffaert M; Gagiano CA
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
    Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
    J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
    DeMartinis NA; Yeung PP; Entsuah R; Manley AL
    J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
    J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
    Katona C; Hansen T; Olsen CK
    Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L; Biancosino B; Marmai L; Righi R
    J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant.
    Krell HV; Leuchter AF; Morgan M; Cook IA; Abrams M
    J Clin Psychiatry; 2004 Sep; 65(9):1174-9. PubMed ID: 15367043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.